Close

Leerink Partners Maintains Bullish View on Trillium Therapeutics (TRIL) as TTI-621 Advances into Phase Ib Expansion Cohort Enrollment

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 4/24/2024

1. TSLA
2. ENPH
3. TXN
4. BA
5. SPOT
6. META
7. V
8. IBM
9. KMB
10. HCP


Go back to Leerink Partners Maintains Bullish View on Trillium Therapeutics (TRIL) as TTI-621 Advances into Phase Ib Expansion Cohort Enrollment
(NASDAQ: TRIL) Delayed: 18.44 --0 (-0%)
Previous Close $18.44    52 Week High $17.70 
Open $18.44    52 Week Low $6.62 
Day High $18.44    P/E N/A 
Day Low $18.44    EPS $0.00 
Volume 123,522